Article: GENE THERAPY.

Balancing the Promise With the Reality

On September 17, 1999, four days after receiving a gene therapy infusion at the University of Pennsylvania, a young man from Arizona who had a genetic disease known as Ornithine Transcarbamylase Deficiency (OTC) died. His death--the first that could be directly linked to gene therapy--electrified the scientific community and triggered a national debate that will have a powerful impact on the future of gene therapy experiments and how they are approved and monitored. These are profound and important questions left unanswered, but for Jesse Gelsinger, the 18-year-old who died, and perhaps for others, it is a debate that came ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!